[Pharmacokinetics of bendamustin (Cytostasan) in B6D2F1-mice].
The pharmacokinetics of bendamustine, (1; Cytostasan), an alkylating antineoplastic agent of the N-lost group, was investigated in B6D2F1 mice. After i.v. injection of the maximally tolerated dose of 50 mg/kg a rapid decrease of the unchanged drug in plasma (MRT 21.9 min) and slowly decreasing levels of mono-, dihydroxy and beta-hydroxy-1 were observed. Variations of the age of the animals as well as of the dose administered did not alter the short MRT of 1. 1 is excreted via the kidneys to a considerable extent showing a similar metabolite pattern in urine as in plasma. The absorption of the drug from the gastrointestinal tract is incomplete resulting in an absolute bioavailability of about 40%.
Weber
H
H
Institut für Mikrobiologie und Experimentelle Therapie, Jena.
Amlacher
R
R
Preiss
R
R
Hoffmann
H
H
D000284:Administration, Oral; D000818:Animals; D000069461:Bendamustine Hydrochloride; D001682:Biological Availability; D002851:Chromatography, High Pressure Liquid; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007408:Intestinal Absorption; D051379:Mice; D008815:Mice, Inbred Strains; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics*
D009588:Nitrogen Mustard Compounds; D000069461:Bendamustine Hydrochloride
Pharmakokinetik von Bendamustin (Cytostasan) an B6D2F1-Mäusen.